A Phase I Trial of B7-Transfected or Parental Lethally Irradiated Allogeneic Melanoma Cell Lines to Induce Cell-Mediated Immunity Against Tumor-Associated Antigen Presented by HLA-A2 or HLA-A1 in Patients with Stage IV Melanoma. National Institutes of Health, Bethesda, Maryland